Novo Nordisk Partners with Hims & Hers to Offer Six Ozempic and Wegovy Dosages
Novo Nordisk struck a partnership with Hims & Hers to offer six Ozempic and Wegovy dosage forms via telehealth, dropping a February patent lawsuit and broadening U.S. distribution. However, a Regeneron GIP/GLP-1 rival’s phase III trial matching Wegovy’s weight-loss efficacy intensifies competitive pressure on Novo’s obesity franchise.
1. Telehealth Partnership with Hims & Hers
Novo Nordisk has sealed a strategic agreement under which Hims & Hers will distribute six formulations of Ozempic and Wegovy via its telehealth platform, resolving a patent dispute and enhancing access to FDA-approved obesity therapies across U.S. markets.
2. Escalating Competitive Pressures
A Regeneron GIP/GLP-1 agonist matched Wegovy’s 19% weight-loss efficacy in a phase III trial with fewer gastrointestinal side effects, underscoring intensifying competition that could erode Novo Nordisk’s market share and pressure its pipeline to deliver differentiated treatments.
3. Analyst Perspectives on Growth Outlook
Citi maintains a Neutral stance on Novo Nordisk, highlighting modest upside from the Hims partnership given limited compounded sales, while cautioning that crowded obesity drug competition may constrain revenue growth absent novel product differentiation.